Overview

Study to Assess the Safety and Tolerability of PF-07220060 in Combination With PF-07104091 in Participants With Breast Cancers or Solid Tumors and to Assess the Safety and Tolerability of PF-07220060 and PF-07104091 in Combination With Endocrine The

Status:
Not yet recruiting

Trial end date:
2027-11-03

Target enrollment:

Participant gender:

Summary

To assess the safety and tolerability of increasing doses of PF-07220060 in combination with PF-07104091 and to estimate the Maximum Tolerated Dose (MTD) and/or select the Recommended dose for expansion (RDE) for PF-07220060 in combination with PF-07104091 in participants with breast cancers or solid tumors and to assess the safety and tolerability of the RDE of PF-07220060 and PF-07104091 in combination with Endocrine Therapy in participants with breast cancer.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Pfizer

Treatments:

Fulvestrant
Letrozole